In this episode of LongeCity interview, Liz Parrish, founder of BioViva, discusses her company’s advancements in gene therapies aimed at combating ageing and promoting rejuvenation.

Key Points:

Liz Parrish shares BioViva's progress in gene therapy research for ageing and rejuvenation, including new viral vector delivery methods and the development of biomarker tests. The company is pushing for regulatory changes to make these therapies widely accessible.

• Update on Liz Parrish’s Health: Liz shares updates on her personal health after undergoing gene therapies in 2015, noting that her blood markers remain in a healthy range and her telomere length has slightly increased since the initial therapy.
• Progress in Gene Therapy Research: BioViva is testing a new viral vector delivery method using the cytomegalovirus (CMV) in mice, which has shown promising results, including a 41.2% life extension in treated mice.
• Viral Vector Advancements: The new delivery method can carry larger therapeutic payloads than previous viral vectors and is redosable without immune rejection, making it more efficient for human applications.
• Focus on Gene Therapy for Ageing: BioViva is dedicated to using gene therapy to treat ageing by targeting upstream cellular mechanisms, which they believe can address many of the downstream effects of ageing, such as inflammation and cellular senescence.
• Development of Ageing Biomarker Tests: BioViva has branched into developing and offering tests for ageing biomarkers like telomere length, NAD levels, and senescent cells, to support data collection and research on human ageing.
• Future Research and Regulatory Hurdles: Parrish emphasizes the need for a new regulatory framework to accelerate human testing of gene therapies, aiming to provide access to life-saving treatments for biological ageing.